Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer naming Leo Varadkar .
Filed returns
20
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Jan–Apr 2023 | Pfizer | Economic Development and Industry | Pfizer recent 1.2 billion euro investment in Ireland operations creating 400-500 jobs (Public policy or programme) | 13 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | Health | Ireland's pricing and reimbursement system and funding for new medicines (Public policy or programme) | 14 | On lobbying.ie |
| Jan–Apr 2023 | Pfizer | EU Affairs | EU Pharmaceutical Legislation (Legislation) | 3 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Energy and Natural Resources | Potential energy shortages (Public policy or programme) | 7 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Budgetary matters | Budget 2023 (Public policy or programme) | 8 | On lobbying.ie |
| Sep–Dec 2022 | Pfizer | Economic Development and Industry | COVID-19 Trips waiver - vaccines and therapeutics (Public policy or programme) | 7 | On lobbying.ie |
| May–Aug 2022 | Pfizer | Budgetary matters | Budget 2023 (Public policy or programme) | 9 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | EU Affairs | Highlight Pfizer concerns re proposed EU vaccine export restrictions and how this could impact Pfizer's ability to manufacture the COVID 19 vaccine and provide supply globally (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2021 | Pfizer | Health | Updates in relation to Pfizer COVID 19 vaccine including global production, Ireland volumes and company colleague vaccination programme (Matters involving public funds) | 10 | On lobbying.ie |
| Sep–Dec 2020 | Pfizer | Health | Highlight Ireland's slowness in reimbursing innovative medicines compared to other European countries and outline factors contributing to this (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2020 | Pfizer | Health | Discussions in relation to Pfizer/BioNtech progress in development of a vaccine for COVID 19 (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Economic Development and Industry | Welcomed committment to corporation tax policy and a supportive environment for FDI as outlined in the Programme for Government (Public policy or programme) | 28 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Health | Highlighted discussions on extension of industry Supply Agreement and the importance of ensuring expenditure is efficently managed to ensure Irish patients can access innovative medicines; welcomed plans to progress the… (Public policy or programme) | 28 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Health | Provided information about Pfizer's research into a COVID-19 vaccine, meeting sought with MoH/DoH. (Public policy or programme) | 29 | On lobbying.ie |
| Jan–Apr 2018 | Pfizer | Taxation | Global competition for FDI and life sciences investment continues to intensify and Ireland continues to compete for such investment. Pfizer has extensive operations in Ireland where many of Pfizer's leading and newest… (Public policy or programme) | 21 | On lobbying.ie |
| Jan–Apr 2018 | Pfizer | Health | Pfizer is seeking reimbursement for a new treatment for metatastic breast cancer which is reimbursed in the majority of EU countries but not yet in Ireland. Ireland has become one of the slowest countries in Europe to… (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Pfizer is seeking reimbursement for a new treatment for metatastic breast cancer which is reimbursed in the majority of EU countries but not yet in Ireland. Ireland has become one of the slowest countries in Europe to… (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Economic Development and Industry | Global competition for foreign direct investment continues to intensify and Ireland continues to compete for such investment. Pfizer has extensive operations in Ireland where many of Pfizer's leading and newest… (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Health | Ireland has now become one of the slowest countries in Europe to reimburse innovative medicines for patients. HTA assessment is prolonged and decisions after HTA are exceptionally slow with the majority of medicines… (Public policy or programme) | 12 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Economic Development and Industry | The Companies Act 2014 allowed for a Ministerial exemption from changing a company name to include the word 'unlimited' in the company name. This change would create significant administrative and cost burden for five… (Legislation) | 11 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 9 | 45.0% | |
| Economic Development and Industry | 5 | 25.0% | |
| Budgetary matters | 2 | 10.0% | |
| EU Affairs | 2 | 10.0% | |
| Energy and Natural Resources | 1 | 5.0% | |
| Taxation | 1 | 5.0% |